Gene Techno Science Co., Ltd.

Hokkaido University

Astellas Pharma Gmbh

Juridical Foundation the Chemo-sero-therapeutic Research Institute

Toshimitsu Uede

Shigeyuki Kon

Masashi Kanayama

Daisuke Kurotaki

Hiroaki Maeda

Naoya Tsurushita

J Yun Tso

Shankar Kumar

Toshihiro Nakashima

Masaharu Torikai

Yutaka Matsui

Hirofumi Higuchi

Nobuchika Yamamoto

Chiemi Kimura

Daisuke Fujikura

Yoshiyuki Tokieda

The problems: It is an object of the present invention to provide an immune regulating agent capable of modulating a receptor function concerning immune regulation of DR6, and a method for screening thereof. The object aims to provide: The present invention relates to an immune regulating agent containing a physiologically active substance having an ability to bind specifically to DR6 and an ability to regulate signal transduction induced by specific binding between DR6 and Sdc1, as an active component. The immune regulating agent of the present invention can be used for treating or preventing diseases caused by excessive or abnormal immune response in mammals or diseases for which enhancement of immune function is desired in mammals, as an immune regulating agent based on a hitherto unknown mechanism, capable of regulating signal transduction induced by specific binding between DR6 and Sdc1.

Anti-DR6 antibodies and methods of immune regulation

The present invention relates to an anti-human &#x3b1;9 integrin antibody. More particularly, the present invention relates to: a monoclonal antibody, a chimeric antibody, a humanized antibody and a human antibody that specifically recognize human &#x3b1;9 integrin; a hybridoma cell that produces the monoclonal antibody; a method for producing the monoclonal antibody; a method for producing the hybridoma cell; a therapeutic agent comprising the anti-human &#x3b1;9 integrin antibody; a diagnostic agent comprising the human &#x3b1;9 integrin antibody; and a method for screening for a compound that inhibits the activity of human &#x3b1;9 integrin.

Anti-human &#x3b1;9 integrin antibody and use thereof

The present invention provides a monoclonal antibody which specifically recognizes RGD in the amino acid sequence of extracellular matrix proteins of a human and a mouse. By specifically inhibiting the RGD sequence-mediated adhesion, exertion of efficient effects on diseases such as inflammation, cancer, infectious disease, autoimmune diseases and osteoporosis and reduction in adverse effects can be expected at the same time. Therefore, better treatment methods can be provided to these diseases.

Antibody against RGD in amino acid sequence of extracellular matrix protein and production method and use of the same

The present invention provides humanized antibodies that immunospecifically recognize the RGD sequence. Some of these antibodies inhibit the biological functions of the RGD proteins, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with RGD proteins, including cancer, e.g., the growth and metastasis of a cancer cell, and inflammatory diseases, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, endometriosis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease, and so forth.

Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof

A remedy for cancer obtained from a different viewpoint from the viewpoints employed in developing the existing anticancer drugs, i.e., focusing on the intercellular adhesion of cancer cells. Namely, provided is a remedy for cancer with fewer side effects which inhibits the proliferation of cancer cells and the intercellular adhesion of cancer cells. Also provided is an antibody, which recognizes the disintegrin domain of ADAM-15 and is usable as an anticancer agent, and so on. An antibody, which recognizes the disintegrin domain of ADAM-15 but does not recognize the RGD sequence or loop region in the disintegrin domain of ADAM-15, and so on; an antibody, which inhibits ADAM-15 and integrin &#x3b1;v&#x3b2;3-dependent cell adhesion, and so on; and an antibody, which inhibits ADAM-15 and integrin &#x3b1;v&#x3b2;1-dependent cell adhesion, and so on.

Anti-ADAM-15 antibodies and utilization of the same

The present invention relates to: an antibody, particularly a monoclonal antibody, a chimeric antibody, a humanized antibody and a human antibody, which specifically recognize human &#x3b1;9 integrin; a hybridoma cell which produces the monoclonal antibody; a method for producing the monoclonal antibody; a method for producing the hybridoma cell; a therapeutic agent comprising the anti-human &#x3b1;9 integrin antibody; a diagnostic agent comprising the human &#x3b1;9 integrin antibody; and a method for screening a compound which inhibits the activity of human &#x3b1;9 integrin.

Antihuman &#x3b1;9 integrin antibody and use of the same

The present invention provides an anti-mouse &#x3b1;9 integrin antibody, an anti-human &#x3b1;9 integrin antibody, a hybridoma producing any of the antibodies, a method of producing any of the antibodies and the hybridoma, and a pharmaceutical composition comprising any of the antibodies. The anti-&#x3b1;9 integrin antibody of the present invention inhibits the &#x3b1;9 integrin function thereby to exhibit therapeutic effects on cancer, e.g., the growth and metastasis of a cancer cell, and an inflammatory disease, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease and the like.

Anti-&#x3b1;9 integrin antibody and the use thereof

A recombinant antibody in which at least the constant regions in the heavy chain and the light chain have been converted into human-origin regions and which inhibits the binding of an integrin recognizing the RGD sequence to osteopontin or its fragment and inhibits the binding of an integrin recognizing the SVVYGLR sequence or a sequence corresponding thereto to osteopontin or its fragment. This antibody is useful as a remedy for autoimmune diseases and a remedy for rheumatism or rheumatoid arthritis. Thus, a method of treating autoimmune diseases, rheumatism or rheumatoid arthritis is provided. This osteopontin antibody is useful in a diagnostic for rheumatism and a method of diagnosing rheumatism too.

Growing community of inventors

Hokkaido, Japan

Toshimitsu Uede